Prestige Consumer Healthcare Inc. (PBH) SEC Filings & Earnings Calls
EquiReason read 14 Prestige Consumer Healthcare Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-14 — Reported a director or officer change (departure, election, appointment or pay arrangement).
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.3B
- P/E TTM
- 13.4
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
14 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Loss of senior operations executive could create temporary gap, but retirement suggests planned transition.
“Retirement effective immediately, no disagreement.”
6 Aug 202610-QCompleted acquisition of OTC Wellness Business for $1.045B, financed with new term loan.acquisitionopen
Figures in the filing · each found in the filing text
| Total revenues · Q2-2026 | $266M | +7% y/y |
| Gross profit margin · Q2-2026 | 51.3% | |
| Contribution margin (North American OTC Healthcare) · North American OTC Healthcare · Q2-2026 | 38.5% | |
| Operating cash flow · Q2-2026 | $71M | -10% y/y |
Risks flagged
Supply chain disruption in sterile eye care
“These shortages have negatively impacted our results of operations, and further shortages may continue to have a negative impact on sales of our eye care products.” · word for word
High leverage from acquisition
“As of June 30, 2026, we had an aggregate of $2.0 billion of outstanding indebtedness.” · word for word
Integration risk from Breathe Right acquisition
“The $1,045.0 million acquisition of the OTC Wellness Business may divert management attention and incur unexpected costs.”
6 Aug 20268-K · 2.02, 7.01Revenue $266M (+6% y/y); Organic sales growth 3.2; Adjusted Diluted EPS $0.98 (+3% y/y); Guidance: Revenue raised from $1,100-$1,121M to $1,290-$1,315M; Adjusted Diluted EPS raised from $4.42-$4.51 to $4.55-$4.65earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2027 | $266M | +7% y/y |
| Organic sales growth · Q1-2027 | 3.2% | |
| Adjusted Diluted EPS · Q1-2027 | $0.98 | +3% y/y |
| Adjusted Non-GAAP Free Cash Flow · Q1-2027 | $84M | +7% y/y |
Guidance
Revenue raised from $1,100-$1,121M to $1,290-$1,315M; Adjusted Diluted EPS raised from $4.42-$4.51 to $4.55-$4.65
Guidance raised to include accretive acquisitions; organic growth outlook maintained at +1% to +3%.
Risks flagged
Clear Eyes variability and challenging consumer backdrop partially offset by strong category performance.
“strength across multiple categories that more than offset a challenging consumer backdrop and Clear Eyes variability” · word for word
Integration risk from Breathe Right and LaCorium acquisitions; near-term costs before synergies realized.
“we expect the acquisitions to become increasingly accretive to profitability and cash flow as we move past the near-term” · word for word
15 Jul 20268-K · 1.01, 2.03Prestige Brands issued $400M 6.250% senior notes due 2034, increasing leverage with customary covenants and redemption provisions.open
Figures in the filing · each found in the filing text
| Aggregate principal amount of senior notes · 2026-07-15 | $400M |
Risks flagged
Increased leverage with 6.250% coupon; interest expense will rise.
“Issued $400M 6.250% senior notes due 2034.”
6 Jul 20268-K · 1.01, 2.03, 7.01Prestige Consumer Healthcare entered a $95M term loan amendment to fund the LaCorium acquisition and launched a $400M senior notes offering due 2034, increasing leverage for M&A.open
Figures in the filing · each found in the filing text
| Term loan amount · Q2-2026 | $95M | |
| Senior unsecured notes amount · Q2-2026 | $400M |
Risks flagged
Increased leverage from $495M new debt may pressure credit metrics and interest coverage.
“Borrowed $95M term loan and $400M notes offering; leverage increase.”
29 Jun 2026DEF 14APrestige Consumer Healthcare Inc. filed its definitive proxy statement for the 2026 annual meeting, including proposals to elect directors, approve executive compensation, and ratify auditor.open
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $1.09B | -4% y/y |
| Net Income · FY2026 | $190M | -11% y/y |
| Adjusted Diluted EPS · FY2026 | $4.38 | -3% y/y |
| Free Cash Flow · FY2026 | $246M | +1% y/y |
| Adjusted EBITDA (AIP) · FY2026 | $354M | -6% y/y |
| GAAP Diluted EPS · FY2026 | $3.91 | -9% y/y |
16 Jun 20268-K · 1.01, 2.01, 2.03, 8.01Prestige Consumer Healthcare completed acquisition of Breathe Right Business for $1.045B cash, funded via new term loan and ABL amendment.acquisitionopen
Figures in the filing · each found in the filing text
| Purchase price · point_in_time | $1.04B |
Risks flagged
Increased leverage from acquisition financing; integration risk.
“Term Loan Credit Agreement, ABL Amendment”
14 May 202610-KRevenue from #1 market position brands as % of total revenue 63.7; International revenue as % of total revenue 16.1; Walmart as % of gross revenues 20; Guidance: No numeric guidance; pending acquisition of Foundation Consumer Brands expecteopen
Figures in the filing · each found in the filing text
| Revenue from #1 market position brands as % of total revenue · FY2026 | 63.7% | |
| International revenue as % of total revenue · FY2026 | 16.1% | |
| Walmart as % of gross revenues · FY2026 | 20.0% | |
| Amazon as % of gross revenues · FY2026 | 15.0% | |
| Revenue from major brands as % of total revenue · FY2026 | 83.5% |
Guidance
No numeric guidance; pending acquisition of Foundation Consumer Brands expected to close H1 FY2027
No explicit financial guidance; strategic focus on acquisitions and international growth; pending deal indicates confidence.
Risks flagged
Customer concentration risk
“During 2026, Walmart accounted for approximately 20%... and Amazon accounted for approximately 15%... of our gross revenues.”
Regulatory compliance cost for sterile products
“Heightened regulatory activity and expectations worldwide, particularly for sterile eye care products, have contributed to ongoing manufacturing disruptions and capacity constraints across the industry.” · word for word
Input cost inflation and tariff risk
“In periods of high inflation we have experienced and may continue to experience frequent increases in prices of products due to fluctuations in input costs such as raw material, energy costs, packaging components and labor costs.” · word for word
Private label competition
“We are experiencing continued competition from 'private label' products introduced by major retail chains.” · word for word
13 May 20268-K · 1.01, 2.02, 7.01Prestige Consumer Healthcare reported Q4 FY2026 revenue of $281.6M (down 5% YoY) and FY2026 revenue of $1.0887B (down 4.3% YoY), with adjusted diluted EPS of $1.23 and $4.38 respectively. Also announced acquisition of LaCorium Health and prearningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $1.09B | -4% y/y |
| Net Income · FY2026 | $190M | -11% y/y |
| Adjusted Diluted EPS · FY2026 | $4.38 | -3% y/y |
| Free Cash Flow · FY2026 | $246M | |
| Q4 Revenue · Q4-2026 | $282M | -5% y/y |
| Q4 Net Income · Q4-2026 | $54M | +8% y/y |
| Q4 Adjusted Diluted EPS · Q4-2026 | $1.23 | -7% y/y |
| North American OTC Healthcare Segment Revenue · North American OTC Healthcare · Q4-2026 | $235M | -6% y/y |
Guidance
Organic revenue growth and adjusted diluted EPS growth of 1% to 3%
Guidance for FY2027 organic revenue growth and adjusted diluted EPS growth of 1% to 3%, excluding acquisitions.
Risks flagged
Supply constraint for Clear Eyes product limits revenue potential.
“limited ability to supply demand for Clear Eyes” · word for word
Shipping disruptions in the Middle East impacted Q4 results.
“fourth quarter shipping disruptions in the Middle East” · word for word
20 Mar 20268-K · 1.01, 7.01, 8.01Prestige Consumer Healthcare announces agreement to acquire Breathe Right brand (nasal strips) for ~$200M revenue, 70%+ gross margin, 45%+ EBITDA margin. Financed with cash and new term loan; pro-forma net leverage ~4.0x.acquisitionopen
Figures in the filing · each found in the filing text
| Revenue · Breathe Right · FY2026 | $200M | |
| Gross Margin · Breathe Right · FY2026 | 70.0% | |
| EBITDA Margin · Breathe Right · FY2026 | 45.0% | |
| Net Leverage · Pro-forma · FY2026 | $4.00 | |
| Market Share · Nasal Strips · FY2026 | 60.0% | |
| Revenue · Breathe Right · FY2026 | $125M | |
| Household Penetration Rate · Breathe Right · FY2026 | 3.0% | |
| Repeat Rate · Breathe Right · FY2026 | 89.0% |
Risks flagged
Integration and execution risk for Breathe Right acquisition, including potential supply chain disruptions and inflationary pressures.
“ability of the Company’s manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and supply disruption” · word for word
Tariff and trade action exposure could impact costs or supply chain.
“evolving U.S. and international tariffs and trade actions” · word for word
Geopolitical instability may affect international operations (~15% revenue international).
“geopolitical instability” · word for word
5 Feb 202610-QPrestige Consumer Healthcare reported Q3 FY2026 revenue of $283.4M, down 2.4% YoY, with gross margin flat but international margin declining 280 bps due to inflation; supply shortages in eye care persist.earningsopen
Figures in the filing · each found in the filing text
| Total Revenue · Q3-2026 | $283M | -2% y/y |
| North American OTC Healthcare Gross Margin · North American OTC Healthcare · Q3-2026 | 55.5% | |
| International OTC Healthcare Gross Margin · International OTC Healthcare · Q3-2026 | 55.9% | |
| Net Cash Provided by Operating Activities · 9M-2026 | $215M | +13% y/y |
Risks flagged
Supply Chain Disruption
“Certain of our third-party manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of our products, particularly eye care products. These shortages have negatively impacted our results of operations, and we expect further shortages will continue to have a negative impact on our sales.”
Customer Concentration
“The $3.5 million increase in general and administrative expenses was primarily due to an increase in our allowance for doubtful accounts pertaining to one specific customer.” · word for word
Tariff and Trade Policy Risk
“Potential changes in export/import and trade laws, regulations and policies, including any increased trade restrictions or tariffs and changes in priorities of the current U.S. administration.” · word for word
Debt Maturity Risk
“As of December 31, 2025, we had an aggregate of $1.0 billion of outstanding indebtedness... $400.0 million of 5.125% 2019 senior unsecured notes, which mature on January 15, 2028.” · word for word
5 Feb 20268-K · 2.02, 7.01Revenue $283M (-2% y/y); Adjusted diluted EPS $1.14 (-7% y/y); Diluted EPS $0.97 (-20% y/y); Guidance: FY2026 net sales outlook narrowed to ~$1.1Bearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2026 | $283M | -2% y/y |
| Adjusted diluted EPS · Q3-2026 | $1.14 | -7% y/y |
| Diluted EPS · Q3-2026 | $0.97 | -21% y/y |
| Nine-month revenue · 9M-2026 | $807M | -4% y/y |
| Nine-month adjusted diluted EPS · 9M-2026 | $3.16 | -1% y/y |
| Free cash flow (9M) · 9M-2026 | $209M | +13% y/y |
Guidance
FY2026 net sales outlook narrowed to ~$1.1B
PBH narrowed FY2026 revenue outlook to ~$1.1B, reflecting continued challenging consumer environment. Revenue exceeded Q3 expectations.
Risks flagged
Clear Eyes supply constraints limiting revenue; challenging consumer environment.
“The revenue decline versus the prior year comparable period was primarily driven by lower Ear & Eye Care category sales as a result of limited ability to supply demand for Clear Eyes” · word for word
6 Nov 20258-K · 2.02, 7.01Revenue $274M (-3% y/y); Net income $42M (-22% y/y); Non-GAAP adjusted net income $52M (-4% y/y); Guidance: FY2026 adjusted diluted EPS $4.54-$4.58 (high end of previous range); free cash flow $245M+earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $274M | -3% y/y |
| Net income · Q2-2026 | $42M | -22% y/y |
| Non-GAAP adjusted net income · Q2-2026 | $53M | -4% y/y |
| Diluted earnings per share · Q2-2026 | $0.86 | -21% y/y |
| Non-GAAP adjusted diluted earnings per share · Q2-2026 | $1.07 | -2% y/y |
| Net cash provided by operating activities (H1) · H1-2026 | $137M | +10% y/y |
| Non-GAAP free cash flow (H1) · H1-2026 | $134M | +10% y/y |
| North American OTC Healthcare segment revenues · North American OTC Healthcare · Q2-2026 | $231M | -4% y/y |
| International OTC Healthcare segment revenues · International OTC Healthcare · Q2-2026 | $43M | -1% y/y |
| Covenant-defined leverage ratio · Q2-2026 | $2.40 |
Guidance
FY2026 adjusted diluted EPS $4.54-$4.58 (high end of previous range); free cash flow $245M+
Revenue outlook unchanged; EPS guidance raised to high end; free cash flow expected to exceed $245M.
Risks flagged
Clear Eyes supply constraints limiting revenue; capacity rebuilding underway.
“Limited ability to supply demand for Clear Eyes; revenue decline driven by this.” · word for word
Revenue decline in North America OTC segment.
“North America OTC revenue -3.8% YoY.”
6 Nov 202510-QPrestige Consumer Healthcare reported Q3 2025 revenue decline of 3.4% YoY, driven by supply constraints in Eye & Ear Care and input cost inflation.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q3-2025 | $274M | -3% y/y |
| Operating cash flow · 6M-2025 | $136M | +10% y/y |
Risks flagged
Supply chain disruption
“Certain of our third-party manufacturers are currently having, and have had in the past, difficulty meeting demand, which is and has caused shortages of our products, particularly eye care products.” · word for word
Input cost inflation
“We have and may continue to experience shortages, delays and backorders for certain ingredients and products, difficulty scheduling shipping for our products, as well as price increases from many of our suppliers for both shipping and product costs.” · word for word
Consumer demand shift
“We have continued to see changes in the purchasing patterns of our consumers, including a shift in many markets to purchasing our products online” · word for word
Prestige Consumer Healthcare Inc. — questions
- What did Prestige Consumer Healthcare Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 8-K on 2026-08-14 — Reported a director or officer change (departure, election, appointment or pay arrangement)
Every figure on this page comes from Prestige Consumer Healthcare Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.